<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Interstitial Nucleus of the Anterior Commissure</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Hypothalamic Nucleus</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Hypothalamus, at the anterior commissure junction (preoptic region)</td>
</tr>
<tr>
<td class="label">Cell Types</td>
<td>Mixed peptidergic neurons, primarily GABAergic and glutamatergic</td>
</tr>
<tr>
<td class="label">Primary Neurotransmitters</td>
<td>GABA, Glutamate, Oxytocin, Vasopressin, CGRP</td>
</tr>
<tr>
<td class="label">Key Markers</td>
<td>OXT, AVP, CGRP, Calbindin, NeuN, GAD67</td>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000178](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000178)</td>
</tr>
<tr>
<td class="label">Source Region</td>
<td>Neurotransmitter</td>
</tr>
<tr>
<td class="label">Spinal cord</td>
<td>Glutamate, CGRP</td>
</tr>
<tr>
<td class="label">Brainstem nuclei</td>
<td>GABA, Serotonin</td>
</tr>
<tr>
<td class="label">Amygdala</td>
<td>Glutamate, Neurotensin</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>Glutamate</td>
</tr>
<tr>
<td class="label">Paraventricular nucleus</td>
<td>CRH, oxytocin</td>
</tr>
<tr>
<td class="
<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Interstitial Nucleus of the Anterior Commissure</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Hypothalamic Nucleus</td>
</tr>
<tr>
<td class="label">Location</td>
<td>Hypothalamus, at the anterior commissure junction (preoptic region)</td>
</tr>
<tr>
<td class="label">Cell Types</td>
<td>Mixed peptidergic neurons, primarily GABAergic and glutamatergic</td>
</tr>
<tr>
<td class="label">Primary Neurotransmitters</td>
<td>GABA, Glutamate, Oxytocin, Vasopressin, CGRP</td>
</tr>
<tr>
<td class="label">Key Markers</td>
<td>OXT, AVP, CGRP, Calbindin, NeuN, GAD67</td>
</tr>
<tr>
<td class="label">Taxonomy</td>
<td>ID</td>
</tr>
<tr>
<td class="label">Cell Ontology (CL)</td>
<td>[CL:0000178](https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000178)</td>
</tr>
<tr>
<td class="label">Source Region</td>
<td>Neurotransmitter</td>
</tr>
<tr>
<td class="label">Spinal cord</td>
<td>Glutamate, CGRP</td>
</tr>
<tr>
<td class="label">Brainstem nuclei</td>
<td>GABA, Serotonin</td>
</tr>
<tr>
<td class="label">Amygdala</td>
<td>Glutamate, Neurotensin</td>
</tr>
<tr>
<td class="label">Hippocampus</td>
<td>Glutamate</td>
</tr>
<tr>
<td class="label">Paraventricular nucleus</td>
<td>CRH, oxytocin</td>
</tr>
<tr>
<td class="label">Preoptic area</td>
<td>GABA</td>
</tr>
<tr>
<td class="label">Target Region</td>
<td>Neurotransmitter</td>
</tr>
<tr>
<td class="label">Periaqueductal gray</td>
<td>GABA, Glutamate</td>
</tr>
<tr>
<td class="label">Paraventricular nucleus</td>
<td>Oxytocin, GABA</td>
</tr>
<tr>
<td class="label">Dorsal motor nucleus vagus</td>
<td>GABA</td>
</tr>
<tr>
<td class="label">Spinal cord</td>
<td>Glutamate, 5-HT</td>
</tr>
<tr>
<td class="label">Thalamic nuclei</td>
<td>Glutamate</td>
</tr>
<tr>
<td class="label">Lateral septum</td>
<td>Peptides</td>
</tr>
<tr>
<td class="label">Disease</td>
<td>INAC Involvement</td>
</tr>
<tr>
<td class="label">Lewy Body Dementia</td>
<td>Early autonomic failure, Lewy body pathology in hypothalamic nuclei</td>
</tr>
<tr>
<td class="label">Multiple System Atrophy</td>
<td>Severe autonomic failure due to widespread hypothalamic involvement</td>
</tr>
<tr>
<td class="label">Progressive Supranuclear Palsy</td>
<td>Sleep disruption, gait instability related to brainstem connectivity</td>
</tr>
<tr>
<td class="label">Huntington's Disease</td>
<td>Hypothalamic dysfunction contributes to metabolic and sleep abnormalities</td>
</tr>
<tr>
<td class="label">Target</td>
<td>Approach</td>
</tr>
<tr>
<td class="label">Autonomic dysfunction</td>
<td>Midodrine, fludrocortisone</td>
</tr>
<tr>
<td class="label">Sleep disorders</td>
<td>Melatonin agonists, clonazepam</td>
</tr>
<tr>
<td class="label">Pain management</td>
<td>Gabapentinoids, opioids</td>
</tr>
<tr>
<td class="label">Oxytocin deficiency</td>
<td>Intranasal oxytocin</td>
</tr>
</table>
The Interstitial Nucleus of the Anterior Commissure (INAC) is a small but anatomically distinct hypothalamic nucleus situated at the junction where the anterior commissure traverses the midline. While historically understudied compared to other hypothalamic nuclei, emerging research has revealed important roles in autonomic regulation, pain modulation, social behavior, and stress responses—all functions that become dysregulated in neurodegenerative diseases. [@behbehani1995]
The INAC is positioned at the midline of the basal forebrain, directly adjacent to the anterior commissure as it passes from left to right hemispheres. This strategic positioning allows it to serve as a hub for interhemispheric communication and integration of limbic information.
The nucleus contains a heterogeneous population of neurons:
The INAC plays a critical role in descending pain inhibition pathways. Neurons in the INAC project to the periaqueductal gray (PAG), which in turn activates descending serotonergic and noradrenergic pathways to the spinal cord dorsal horn to inhibit nociceptive transmission [1](https://pubmed.ncbi.nlm.nih.gov/7642812/).
Key mechanisms include:
The INAC integrates viscerosensory information and coordinates autonomic responses:
Oxytocin and vasopressin neurons in the INAC are essential for:
The INAC participates in hypothalamic-pituitary-adrenal (HPA) axis regulation:
INAC dysfunction contributes to several hallmark features of Alzheimer's disease:
Autonomic Dysfunction
The INAC is particularly vulnerable in Parkinson's disease due to its connections with basal ganglia structures:
Autonomic Failure
GABAergic System:
Pharmacological:
The study of Interstitial Nucleus Of The Anterior Commissure has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.